Clinical trials: System; Sclerosis
Scleroderma
Scleroderma Treatment With Celution Processed ADRCs Registry
This registry study will assess the safety and performance of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand scleroderma.
- Trial name
- STAR (NCT02328625)
- Sponsor
- Cytori Therapeutics
Sialorrhea, Amyotrophic Lateral Sclerosis
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in parotids and submandibular glands.
- Trial name
- ALS-TOX (NCT01551940)
- Testing
- Botox injection
- Where
- 13 sites in France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Relapsing-Remitting Multiple Sclerosis, Urinary Incontinence
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
The aim of the study is to evaluate the effectiveness of guided versus non guided pelvic floor exercises for urinary incontinence in patients with Relapsing-Remitting Multiple Sclerosis
- Trial name
- NCT03000647
- Testing
- Pelvic floor exercises guided by a physiotherapist, Non guided pelvic floor exercises
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Scleroderma, Systemic
Impact of Education and Training of Modified Rodnan Skin Scoring on the Reliability of Test
The aim of the study is evaluating the efficacy of organized education process of the modified Rodnan Skin Score (MRSS) in the systemic sclerosis.
- Trial name
- NCT03219606
- Testing
- Organized education course of Modified Rodnan Skin Scoring
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Muscular Atrophy, Progressive, Frontotemporal Dementia
- Trial name
- NCT05830214
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alberta
Multiple Sclerosis, Fatigue
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
Multiple Sclerosis (MS) is the most frequent cause of non-traumatic disability in people under 55 years of age. Fatigue is the most frequent and disabling symptom in the disease, and for which there is no effective treatment.
- Trial name
- FETEM (NCT05809414)
- Testing
- Transcranial Magnetic Stimulation, Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule
- Where
- 4 sites in Spain
- Volunteers
- 144 people
- Sponsor
- Hospital San Carlos, Madrid
Multiple Sclerosis, Progressive Multiple Sclerosis
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
The primary objective of the study is to investigate neuroregenerative efficacy (proof of concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological parameters in patients with progressive MS.
- Trial name
- SMART-MS (NCT04749667)
- Testing
- MSCs, Saline
- Where
- 4 sites in Norway
- Volunteers
- 18 people
- Sponsor
- Haukeland University Hospital
Relapsing-Remitting Multiple Sclerosis
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy.
- Trial name
- SOSTOS (NCT05090371)
- Testing
- Ofatumumab, Disease modifying treatment (DMT)
- Where
- 43 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Brain-Computer Interface Communication Device for People With ALS
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.
- Trial name
- NCT07871071
- Testing
- Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cognixion
Epilepsy, Drug Resistant
Piriform Cortex Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Piriform cortex as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy…
- Trial name
- NCT07128563
- Testing
- piriform cortex-DBS
- Volunteers
- 5 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic inflammatory disorder affecting the central nervous system that is characterized pathologically by focal demyelinating lesions in the brain parenchyma.
- Trial name
- NCT02253264
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Systemic Sclerosis
Exercise in People With Systemic Sclerosis
Raynaud's phenomenon and digital ulceration are two of the most common disease manifestations leading to digital and/or toe pain in systemic sclerosis (SSc).
- Trial name
- SScPF (NCT05234671)
- Testing
- Exercise programme
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- Sheffield Hallam University
Relapsing Remitting Multiple Sclerosis
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with…
- Trial name
- NCT00211887
- Testing
- Interferon beta 1-a, glatiramer acetate
- Where
- 71 sites in United States, Canada
- Volunteers
- 1,008 people
- Sponsor
- Fred Lublin
Multiple Sclerosis
Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis
The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe…
- Trial name
- BFR-MS (NCT04633759)
- Testing
- Blood Flow Restriction Exercise
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Rehabilitation in SOD1 ALS Treated With Tofersen
The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT05725759
- Testing
- Rehabilitation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide.
- Trial name
- ChariotMS (NCT04695080)
- Testing
- Cladribine (MAVENCLAD®)
- Where
- 22 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
Demyelinating Disorders, MCI
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple…
- Conditions
- Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis)
- Trial name
- NCT06999434
- Testing
- [ 18F]3F4AP, [18F]MK6240, [11C]PIB
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Yale University
Multiple Sclerosis
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who…
- Trial name
- NCT00240006
- Testing
- Shared Solutions® plus MS Center v. Shared Solutions®
- Volunteers
- 307 people
- Sponsor
- Teva Neuroscience, Inc.